The Economic Costs of Diabetes: Is It Time for a New Treatment Paradigm?

n a series of rigorous and exhaustive descriptive cost analyses conducted over the past decade, the American Diabetes Association (ADA) has documented an inexorable increase in the cost of diabetes in the U.S. and its detrimental impact on productivity (1-3). For the 2012 study, the ADA estimated that there were 22.3 million Americans diagnosed with diabetes (3). These patients incurred \$306 billion in direct medical costs, more than 1 of 5 dollars spent on medical care in the U.S. (3). The direct medical costs attributed to diabetes, that is, the costs of medical care for people with diabetes in excess of those that would be expected in the absence of diabetes, were \$176 billion or approximately 1 of 8 dollars spent on medical care in the U.S. (3). Americans with diagnosed diabetes have annual medical expenditures that are \$7,900 or approximately 2.3 times higher than they would be in the absence of diabetes (\$13,700 vs. \$5,800) (3). Americans with diabetes also incur \$69 billion in costs related to absenteeism, reduced productivity while at work or at home, diabetes-related disability, and premature mortality (3). The increasing economic burden of diabetes is due in large part to the increase in the number of people with diagnosed diabetes. The estimated number of Americans with diagnosed diabetes increased from 12.1 million in 2002 to 17.5 million in 2007 to 22.3 million today (1-3). The increased frequency of chronic complications, particularly cardiovascular and renal disease, changing health care practices, and the wider application of new and expensive technologies and treatments have also contributed to the increasing cost of diabetes. Whatever the causes, diabetes is a major burden to the U.S. health care system and

One of the major limitations of descriptive cost analyses such as those conducted by the ADA is that they do not provide an indication of the value obtained for the money spent. Some insights can, however, be gleaned by looking at where health care dollars are being spent. Fiftynine percent of health care expenditures attributed to diabetes in the U.S. are incurred by the population ≥65 years of age

with diagnosed diabetes, including 65% of health care expenditures attributed to hospital inpatient, nursing/residential facility, hospice, and home health care (3). The population ≥65 years of age also incurs 60% of expenditures for prescription medications used to treat diabetes complications (3). Hospital inpatient care, nursing/ residential facility stays, hospice care, home health services, and prescription medications to treat diabetes complications account for nearly three-quarters of all health care expenditures attributed to diabetes (3). Outpatient care delivered in physicians' offices and hospital outpatient clinics, antidiabetic medications, and diabetic supplies account for less than one-quarter of the health care expenditures attributed to diabetes (3). These findings indicate that the vast majority of health care dollars are being spent for older patients with longstanding diabetes and advanced complications. Fewer health care dollars are being spent for the outpatient management and treatment of diabetes.

The increase in health care expenditures related to the increase in the size of the population with diagnosed diabetes, the large proportion of expenditures incurred by the population ≥65 years of age, and the large proportion of expenditures related to late diabetes complications suggest that interventions to delay or prevent the development of diabetes in at-risk Americans, and treatments to delay or prevent the development of complications and comorbidities in Americans with diagnosed diabetes, may be most effective in stemming the growing economic burden of diabetes.

Randomized controlled clinical trials have clearly demonstrated the efficacy of lifestyle interventions in delaying the onset of type 2 diabetes (4–7). Observational follow-up studies of clinical trials have demonstrated that the benefits of lifestyle interventions persist for 7–20 years (8–10). Translational studies have demonstrated that lifestyle interventions can be adapted and translated into primary care and can achieve short-term weight loss outcomes comparable to those observed in clinical trials (11–13). Lifestyle interventions can also be successfully translated

into community practice through organizations such as YMCAs (14,15) and diabetes self-management education programs (16). In Finland, lifestyle interventions for diabetes prevention have been successfully translated into a National Diabetes Prevention Program and a 1-year followup study has demonstrated effectiveness (17). Randomized controlled clinical trials of pharmacologic interventions have demonstrated that at least 3 classes of oral antidiabetic medications are effective in delaying the onset of type 2 diabetes (6,18,19). By delaying the onset of diabetes, such interventions reduce the cumulative incidence of diabetes complications and result in longer lives and improved quality of life (20).

A recent review of 12 economic analyses conducted by 10 research groups in 9 countries also demonstrated that in 11 of 12 analyses, lifestyle interventions were cost-effective (20). A recent withintrial analysis of resource utilization and outcomes from the Diabetes Prevention Program/Diabetes Prevention Program Outcomes Study confirmed that an intensive lifestyle intervention is extremely cost-effective and metformin treatment is possibly cost-saving over 10 years (21).

Randomized controlled clinical trials have also demonstrated that intensive glycemic management can delay the onset of microvascular, neuropathic, and cardiovascular complications in people with both type 1 and type 2 diabetes, and that the benefits of early intensive treatment persist over time (22,23). Randomized controlled clinical trials have also demonstrated that blood pressure management (target blood pressure 135/80 mmHg) and lipid management using statin medications can delay or prevent the development of adverse cardiovascular outcomes (24.25)

The growing economic and societal burden of diabetes as documented by the ADA in this issue of *Diabetes Care* highlights the urgent need to implement interventions to delay the development of type 2 diabetes (3). Both intensive lifestyle and pharmacologic interventions are proveneffective and cost-effective. Health policy should support their implementation. Complimentary societal interventions to

Commentary

delay the onset of type 2 diabetes include school-based health promotion programs and interventions that address advertising, food availability and price, the built and workplace environment, and even tax policy. In addition, early aggressive management of glycemia and cardiovascular risk factors must be implemented for persons diagnosed with diabetes. Increasing access to care, including selfmanagement education and nutritional counseling, and ensuring access to necessary treatments and supplies are critical, especially in light of the proven value of early intensive treatment in preventing chronic complications. The cost estimates provided by the ADA from 2002, 2007, and 2012 show that the economic and societal burden of diabetes is growing in the U.S. This trend underscores the importance of prevention and interventions to mitigate the complications of diabetes.

WILLIAM H. HERMAN, MD, MPH

From the Departments of Internal Medicine and Epidemiology, University of Michigan, Ann Arbor, Michigan.

Corresponding author: William H. Herman, wherman@umich.edu.

DOI: 10.2337/dc13-0270

© 2013 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.

Acknowledgments—No potential conflicts of interest relevant to this article were reported.

References

- American Diabetes Association. Economic costs of diabetes in the U.S. in 2002. Diabetes Care 2003;26:917–932
- 2. American Diabetes Association. Economic costs of diabetes in the U.S. in 2007. Diabetes Care 2008;31:596–615
- 3. American Diabetes Association. Economic costs of diabetes in the U.S. in 2012. Diabetes Care 2013;36:1033–1046
- 4. Pan XR, Li GW, Hu YH, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care 1997;20:537–544
- 5. Tuomilehto J, Lindström J, Eriksson JG, et al.; Finnish Diabetes Prevention Study Group.

- Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001;344:1343–1350
- Knowler WC, Barrett-Connor E, Fowler SE, et al.; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346:393–403
- 7. Ramachandran A, Snehalatha C, Mary S, Mukesh B, Bhaskar AD, Vijay V; Indian Diabetes Prevention Programme (IDPP). The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). Diabetologia 2006;49:289–297
- 8. Li G, Zhang P, Wang J, et al. The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20-year follow-up study. Lancet 2008;371:1783–1789
- Lindström J, Ilanne-Parikka P, Peltonen M, et al.; Finnish Diabetes Prevention Study Group. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study. Lancet 2006;368:1673– 1679
- Knowler WC, Fowler SE, Hamman RF, et al.; Diabetes Prevention Program Research Group. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet 2009;374:1677–1686
- Appel LJ, Clark JM, Yeh HC, et al. Comparative effectiveness of weight-loss interventions in clinical practice. N Engl J Med 2011;365:1959–1968
- Wadden TA, Volger S, Sarwer DB, et al. A two-year randomized trial of obesity treatment in primary care practice. N Engl J Med 2011;365:1969–1979
- Ma J, Yank V, Xiao L, et al. Translating the Diabetes Prevention Program lifestyle intervention for weight loss into primary care: a randomized trial. Arch Intern Med. 10 December 2012 [Epub ahead of print]
- Ackermann RT, Finch EA, Brizendine E, Zhou H, Marrero DG. Translating the Diabetes Prevention Program into the community. The DEPLOY Pilot Study. Am J Prev Med 2008;35:357–363
- 15. Ackermann RT, Finch EA, Caffrey HM, Lipscomb ER, Hays LM, Saha C. Long-term effects of a community-based lifestyle intervention to prevent type 2 diabetes: the DEPLOY extension pilot study. Chronic Illn 2011;7:279–290

- 16. Harwell TS, Vanderwood KK, Hall TO, Butcher MK, Helgerson SD; Montana Cardiovascular Disease and Diabetes Prevention Workgroup. Factors associated with achieving a weight loss goal among participants in an adapted Diabetes Prevention Program. Prim Care Diabetes 2011;5: 125–129
- 17. Saaristo T, Moilanen L, Korpi-Hyövälti E, et al. Lifestyle intervention for prevention of type 2 diabetes in primary health care: one-year follow-up of the Finnish National Diabetes Prevention Program (FIN-D2D). Diabetes Care 2010;33:2146–2151
- Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M; STOP-NIDDM Trial Research Group. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 2002;359:2072–2077
- 19. DeFronzo RA, Tripathy D, Schwenke DC, et al.; ACT NOW Study. Pioglitazone for diabetes prevention in impaired glucose tolerance. N Engl J Med 2011;364: 1104–1115
- Saha S, Gerdtham UG, Johansson P. Economic evaluation of lifestyle interventions for preventing diabetes and cardiovascular diseases. Int J Environ Res Public Health 2010;7:3150–3195
- 21. Diabetes Prevention Program Research Group. The 10-year cost-effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent-to-treat analysis of the DPP/DPPOS. Diabetes Care 2012;35:723–730
- 22. Nathan DM, Cleary PA, Backlund JY, et al.; Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005;353:2643–2653
- 23. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577–1589
- 24. Hansson L, Zanchetti A, Carruthers SG, et al.; HOT Study Group. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998;351:1755–1762
- 25. Collins R, Armitage J, Parish S, Sleigh P, Peto R; Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003;361:2005–2016